Clinical Efficacy of Pioglitazone with Ethinylestradiol-cyproterone Acetate for Treatment of Polycystic Ovary Syndrome

This study explored the clinical efficacy of pioglitazone with ethinylestradiol-cyproterone acetate for treating polycystic ovary syndrome (PCOS). Totally 74 patients with PCOS were divided to two groups (control: 37 cases; observation: 37 cases) which received treatment using ethinylestradiol-cyproterone acetate and treatment using pioglitazone hydrochloride based on ethinylestradiol-cyproterone acetate, respectively. The efficacy, sex hormones, blood glucose and lipid indexes, ovulation and pregnancy outcomes and adverse reactions were observed. At the end of treatment, comparing to control group, in observation group total ef-fective rate obviously ascended, serum LH, FSH, A2 and E2 contents obviously declined, FBG and HOMA-IR contents obviously declined, FINS content obviously ascended, serum TC, HDL and TG contents obviously declined, ovarian volume and BMI obviously declined, pregnancy and ovulation rates obviously ascended, and ovarian hyperstimulation syndrome rate obviously declined. Pioglitazone combined with ethinylestradiol-cy-proterone acetate has a synergistic effect in treatment of PCOS. It can effectively regulate the sex hormones, blood glucose and blood lipid levels, and promote the recovery of ovarian function, thus improving the ovula-tion rate and pregnancy outcomes.